Who owns CorMedix Inc. (CRMD)? Elite investor 13F holders
2 tracked elite investors reported holding CorMedix Inc as of 2026-09-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | CORMEDIX INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 2544604.00 USD | 330468.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | CORMEDIX INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 420243.00 USD | 54577.000000 | Shares | buy | Original filing |
| Gotham Asset Management | CORMEDIX INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.